This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: Quanta

The following ratings changes were generated on Wednesday, Nov. 12.

We've downgraded Alcon (ACL), which engages in the development, manufacture, and marketing of pharmaceuticals, surgical equipment and devices and consumer eye care products to treat eye diseases and disorders, from buy to hold. Strengths include its impressive record of earnings per share growth, revenue growth and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year.

Alcon reported significant earnings-per-share improvements in the most recent quarter compared with the same quarter a year ago, and during the past fiscal year, it earned $5.25 vs. $4.37 in the prior year. This year, the market expects further improvement to $5.92. Since the same quarter last year, revenue rose by 14.1%, compared with the industry average of 18% growth. The 0.31 debt-to-equity ratio is low, but it's higher than the industry average. The quick ratio of 1.69 is high, demonstrating strong liquidity.

Net income decreased by 51% over the same quarter one year prior, to $627.1 million, outperforming the S&P 500 but underperforming the health care equipment and supplies industry. Shares are down 43.42% on the year, an underperformance of the S&P 500. Naturally, the overall market trend is bound to be a significant factor, and in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ICH $7.08 0.00%
AYI $167.26 -0.29%
ESGR $141.76 -0.13%
LECO $67.35 0.48%
PWR $29.47 0.65%


DOW 18,076.97 -3.17 -0.02%
S&P 500 2,112.92 -4.77 -0.23%
NASDAQ 5,063.92 -28.1650 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs